Fluoroquinolones and Tendon Injury: A Signal-Evaluation Case Study

Fluoroquinolone-associated tendinopathy and tendon rupture illustrate how a safety signal can progress from unusual clinical observations to a characterised class risk with identifiable susceptibility factors and targeted restrictions.

Purpose of the Case Study

The safety question is more precise than “fluoroquinolones cause musculoskeletal adverse effects.” The relevant phenotype includes tendon pain and inflammation, tendinopathy and structural tendon rupture, with the Achilles tendon particularly prominent.

This matters because a symptom report and an objectively confirmed tendon rupture contribute different evidentiary weight.

The Value of a Distinctive Phenotype

Tendon rupture can often be anatomically localised and confirmed clinically, by imaging or at surgery. That makes it more specific for signal evaluation than nonspecific pain.

Early reports therefore generated a plausible hypothesis even though they could not estimate incidence or exclude background tendon injury.

Temporal Pattern

The signal became more informative when timing was characterised. EMA's EU review states that tendon injury can occur within approximately 48 hours of starting a fluoroquinolone and can also present months after treatment has stopped.

This creates two important lessons.

First, a fixed narrow latency window would miss relevant cases. Second, delayed presentation means that the antibiotic exposure may no longer be obvious when the tendon event is diagnosed.

Risk Factors and Effect Modification

The signal was refined further by identifying patients at increased risk. EMA highlights greater concern in older patients, patients with renal impairment, solid-organ transplant recipients and patients receiving corticosteroids.

Concomitant corticosteroid use is especially important because it demonstrates effect modification: the safety effect is not uniform across all exposed patients.

The pharmacovigilance conclusion therefore evolves from:

fluoroquinolone → tendon injury

to:

fluoroquinolone + susceptible patient or co-exposure → increased tendon-injury risk.

Epidemiological Evidence

Population studies supported an association between fluoroquinolone exposure and tendon disorders, particularly Achilles tendon rupture. Their role was not simply to confirm case reports but to estimate the association in populations with denominators and to examine timing and risk modifiers.

Study interpretation still requires attention to confounding. Infection itself, age, physical activity, corticosteroid exposure, renal disease and underlying tendon disorders can all differ between exposed and comparison groups.

Mechanistic Evidence

Experimental work has proposed effects on tenocytes, extracellular matrix, collagen metabolism, oxidative stress, mitochondrial function and matrix metalloproteinases.

These findings support biological plausibility. They do not establish one complete molecular pathway that explains every clinical tendon rupture.

The clinical association can therefore be well established while the precise mechanism remains incompletely resolved.

Individual-Case Assessment

A useful tendon-injury case review establishes:

• the specific fluoroquinolone;
• start and stop dates;
• onset of tendon symptoms;
• anatomical site;
• imaging or surgical confirmation where available;
• prior tendon disease or injury;
• age and renal function;
• corticosteroid exposure;
• transplantation history;
• physical activity or trauma; and
• clinical course after treatment withdrawal.

A convincing temporal relationship strengthens a case, but a tendon rupture that follows major mechanical trauma months after exposure may carry less causal weight than an atraumatic Achilles injury occurring during treatment in a patient with recognised susceptibility factors.

Dechallenge and Rechallenge

Structural tendon injury does not behave like a rapidly reversible pharmacological symptom. Stopping the antibiotic does not restore a damaged tendon immediately, and delayed events can occur after discontinuation.

The absence of rapid improvement after withdrawal therefore should not be treated as strong evidence against causality.

Intentional rechallenge after a serious tendon reaction would generally be inappropriate. Naturally occurring re-exposure can be informative but should be interpreted cautiously.

Class Signal and Product-Level Questions

Evidence across several fluoroquinolones supported a class safety concern. Nevertheless, spontaneous-report disproportionality differences between individual substances should not be interpreted automatically as differences in incidence.

Product use, indication, route, exposure, reporting behaviour and patient mix can all affect reporting patterns.

EU Regulatory Evolution

The EU-wide review of quinolone and fluoroquinolone antibiotics considered serious, disabling and potentially permanent adverse effects affecting tendons, muscles, joints and the nervous system. Restrictions introduced in 2019 narrowed use of systemic and inhaled fluoroquinolones and strengthened warnings.

EMA advises particular caution in older patients, those with kidney disease and transplant recipients, and advises avoiding combined fluoroquinolone and corticosteroid treatment because tendon risk is increased.

This regulatory response is broader than tendon rupture alone, but the tendon signal contributed to the evidence supporting class-wide restrictions.

Risk Minimisation as Translation of the Signal

Once a signal is characterised, the purpose is not merely to add a warning. Risk minimisation should target the circumstances in which avoidable harm is most likely.

For this signal, relevant measures include:

• restricting use where alternative antibiotics are appropriate;
• avoiding use after previous serious fluoroquinolone reactions;
• caution in higher-risk populations;
• avoiding concomitant corticosteroids where possible; and
• instructing patients to stop treatment and seek medical advice at the first signs of tendon injury according to current product information.

Why Mechanistic Uncertainty Does Not Negate the Signal

The fluoroquinolone example demonstrates that a safety association can become regulatory actionable without a single completely proven molecular mechanism.

The evidence hierarchy is:

clinical phenotype + temporal pattern + epidemiological association + susceptibility factors + experimental plausibility.

Mechanistic evidence strengthens coherence but is not the sole basis of the conclusion.

Potential Failure Modes

1. Define the tendon phenotype precisely.
2. Reconstruct exposure and symptom timing, including delayed presentation.
3. Review objective confirmation and anatomical site.
4. Assess corticosteroids, age, renal impairment, transplantation and mechanical explanations.
5. Compare case patterns across fluoroquinolone substances without treating reporting counts as incidence.
6. Integrate epidemiological and mechanistic evidence.
7. Determine whether risk is class-wide, subgroup-specific or interaction-modified.
8. Connect the conclusion to current risk minimisation.

Inspection and Governance Perspective

An inspector or assessor may examine whether clinically important tendon reports were followed sufficiently, whether recognised risk modifiers were considered, whether the organisation tracked evolving regulatory restrictions, and whether product information and internal safety conclusions remained consistent.

There is no requirement for one particular tendon-adjudication committee or proprietary signal score. The important evidence is a traceable and scientifically defensible assessment.

Relationship With Other QPPV.com Articles

This article complements [[signal-assessment]], [[pharmacoepidemiology-in-pharmacovigilance]], [[causality-assessment-in-pharmacovigilance]] and [[risk-minimisation-effectiveness-evaluation]]. It illustrates how effect modification converts a broad class signal into clinically targeted precautions.

Key Takeaways

Fluoroquinolone-associated tendon injury is a well-characterised class safety concern. The signal became stronger and more useful when the phenotype, timing and higher-risk populations were defined.

Tendon damage can occur early during treatment or after treatment has stopped. Older age, renal impairment, transplantation and corticosteroid exposure are important susceptibility factors identified in current EMA safety information.

The precise molecular mechanism remains less certain than the clinical association. Regulatory action therefore rests on the totality of clinical, epidemiological and experimental evidence rather than one mechanistic explanation.

References

1. European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. 2018/2019 EU regulatory review.
2. European Medicines Agency. Fluoroquinolone antibiotics: reminder of measures to reduce the risk of long-lasting, disabling and potentially irreversible side effects. 2023.
3. van der Linden PD, Sturkenboom MCJM, Herings RMC, et al. Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Archives of Internal Medicine. 2003;163:1801-1807.
4. Morales DR, Slattery J, Pacurariu A, et al. Relative and absolute risk of tendon rupture with fluoroquinolone and concomitant fluoroquinolone/corticosteroid therapy. Clinical Drug Investigation. 2019;39:205-213.
5. Current authorised EU product information for the relevant fluoroquinolone.

Regulatory Note

EU restrictions on systemic and inhaled fluoroquinolones were introduced following an EU-wide review and remain clinically relevant. Current authorised indications and warnings should be checked in the applicable product information. This article describes the historical signal-evaluation logic and should not substitute for current prescribing information.